ST. LOUIS, Dec. 8 /PRNewswire/ -- www.leebio.com, Lee Biosolutions, Inc continues to increase its capacity for stable Human Myeloperoxidase enzyme for clinical diagnostic, pharmaceutical manufacturers and clinical researchers worldwide due to high demand.
Current research on this important Myeloperoxidase protein has expanded from acute lung injury, acute inflammation to multiple sclerosis, diabetes, stroke and gastric cancer prediction. Great deal of worldwide research continues with this important enzyme that Lee Biosolutions produces.
Three Myeloperoxidase isoforms have been purified and identified through ion exchange chromatography by Lee Biosolutions. Human Myeoloperoxidase Isoform A, Myeloperoxidase isoform B and Myeloperoxidase isoform C. MPO C is a popular enzyme among the community of protein structural researchers, including X-ray crystallographers. Lee Biosolutions whole Myeloperoxidase 426- 10 is popular among major Clinical Diagnostic manufacturers.
According to company President Burton Lee, Lee Biosolutions is in constant communication with its customers to determine trends and anticipate product needs before they happen. Innovative purification procedures continue to be developed in order to meet the demands of our clients.
"We understand the critical role our products play in the clinical research process," Lee said. "By maintaining higher purity and quality standards, we aim to provide clients with a wider variety of reliably consistent products which makes us the preferred producer of Myeloperoxidase products."
Press Release Contact Information: Burton Lee President Lee Biosolutions, Inc 314-968-1091 email@example.com
This release was issued through WebWire(R). For more information visit http://www.webwire.com.
|SOURCE Lee Biosolutions, Inc|
Copyright©2008 PR Newswire.
All rights reserved